EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Treatment Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy Using Intratumoral and Peritumoral Radiomics from T2-Weighted and Contrast-Enhanced T1-Weighted MRI

Deok Hyun Jang, Christopher Kolios, Laurentius O Osapoetra, Lakshmanan Sannachi, Belinda Curpen iD, Ana Pejović-Milić, Gregory J Czarnota

Cancers · 30.04.2025 · 17 (9) · 1520

DOI: 10.3390/cancers17091520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 30.04.2025. Verfasst von Deok Hyun Jang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Physical Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council, Terry Fox Research Institute, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Neoadjuvant chemotherapy (NAC) is an integral part of breast cancer management, and response to NAC is an important prognostic factor associated with improved survival outcomes. However, the current standard for response assessment relies on post-surgical histopathological analysis, which limits early therapeutic decision-making and treatment personalization. This study aimed to develop and evaluate a machine learning model that integrates pre-treatment MRI radiomics and clinical features to predict response to NAC in breast cancer patients. (2)

Methods

In this study, a machine learning model was developed to predict breast cancer response to NAC using pre-treatment magnetic resonance imaging (MRI) radiomics and clinical data. Radiomic features were extracted from contrast-enhanced T1-weighted (CE-T1) and T2-weighted (T2) MRI sequences using both intratumoral and peritumoral segmentations. Furthermore, this study uniquely examined two response assessment criteria: (1) pathologic complete response (pCR) versus non-pCR, and (2) clinical response versus non-response. A total of 254 patients with biopsy-confirmed breast cancer who completed NAC were included. Radiomic features (n = 400) and clinical features (n = 7) were analyzed to build a predictive model employing the XGBoost classifier. Performance was measured in terms of accuracy, precision, sensitivity, specificity, F1-score, and AUC. (3)

Results

The integration of radiomic features with clinical data significantly enhanced the predictive performance. For pCR and non-pCR prediction, the combined features model achieved an accuracy of 80% and AUC of 0.85, outperforming both the clinical features model (Accuracy = 68%, AUC = 0.81) and radiomic features model (Accuracy = 66%, AUC = 0.60). Similarly, for the clinical response and non-response prediction, the combined features model achieved an Accuracy of 74% and AUC of 0.75, outperforming both the clinical features model (Accuracy = 63%, AUC = 0.68) and radiomic features model (Accuracy = 66%, AUC = 0.57). (4)

Conclusions

These findings highlight the synergistic effect of integrating clinical data and MRI-based radiomics to improve pre-treatment NAC response prediction, which has the potential to enable more precise and personalized treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

MRIbreast cancermachine learningneoadjuvant chemotherapyradiomicsresponse prediction

Autor:innen und Institutionen

  • Physical Sciences, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
  • Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Department of Physics, Toronto Metropolitan University, Toronto, ON M5B 2K3, Canada.
  • Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5T 1P5, Canada.
  • Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, ON M5T 1P5, Canada.

ORCID-Profile: Belinda Curpen

Förderung

  • Natural Sciences and Engineering Research Council
  • Terry Fox Research Institute
  • Natural Sciences and Engineering Research Council of Canada
  • Terry Fox Research Institute (TFRI)/the Lotte & John Hecht Memorial Foundation

Zitieren

APA

Jang, D. H., Kolios, C., Osapoetra, L. O., Sannachi, L., Curpen, B., Pejović-Milić, A., & Czarnota, G. J. (2025). Pre-Treatment Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy Using Intratumoral and Peritumoral Radiomics from T2-Weighted and Contrast-Enhanced T1-Weighted MRI. Cancers, 17(9), 1520. https://doi.org/10.3390/cancers17091520

Vancouver

Jang DH, Kolios C, Osapoetra LO, Sannachi L, Curpen B, Pejović-Milić A, et al. Pre-Treatment Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy Using Intratumoral and Peritumoral Radiomics from T2-Weighted and Contrast-Enhanced T1-Weighted MRI. Cancers. 2025;17(9):1520. doi:10.3390/cancers17091520

BibTeX
@article{Jang2025,
  author = {Jang, Deok Hyun and Kolios, Christopher and Osapoetra, Laurentius O and Sannachi, Lakshmanan and Curpen, Belinda and Pejović-Milić, Ana and Czarnota, Gregory J},
  title = {Pre-Treatment Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy Using Intratumoral and Peritumoral Radiomics from T2-Weighted and Contrast-Enhanced T1-Weighted MRI},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1520},
  doi = {10.3390/cancers17091520}
}
Kostenlos starten →